HomeCompareATERX vs MRK

ATERX vs MRK: Dividend Comparison 2026

ATERX yields 1.34% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATERX wins by $12.66M in total portfolio value· pulled ahead in Year 4
10 years
ATERX
ATERX
● Live price
1.34%
Share price
$149.57
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.72M
Annual income
$11,119,257.82
Full ATERX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ATERX vs MRK

📍 ATERX pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATERXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATERX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATERX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATERX
Annual income on $10K today (after 15% tax)
$113.66/yr
After 10yr DRIP, annual income (after tax)
$9,451,369.15/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ATERX beats the other by $9,443,040.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATERX + MRK for your $10,000?

ATERX: 50%MRK: 50%
100% MRK50/50100% ATERX
Portfolio after 10yr
$6.39M
Annual income
$5,564,527.98/yr
Blended yield
87.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ATERX
No analyst data
Altman Z
1.2
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATERX buys
0
MRK buys
0
No recent congressional trades found for ATERX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATERXMRK
Forward yield1.34%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$12.72M$56.8K
Annual income after 10y$11,119,257.82$9,798.13
Total dividends collected$12.57M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ATERX vs MRK ($10,000, DRIP)

YearATERX PortfolioATERX Income/yrMRK PortfolioMRK Income/yrGap
1$10,967$267.43$11,206$366.19$239.00MRK
2$12,283$548.23$12,650$502.35$367.00MRK
3$14,291$1,147.69$14,407$694.19$116.00MRK
4← crossover$17,787$2,495.83$16,585$967.82+$1.2KATERX
5$24,839$5,806.38$19,342$1,363.89+$5.5KATERX
6$41,733$15,155.62$22,913$1,947.19+$18.8KATERX
7$92,250$47,596.11$27,662$2,823.89+$64.6KATERX
8$295,364$196,655.87$34,159$4,173.35+$261.2KATERX
9$1,492,947$1,176,907.65$43,337$6,308.80+$1.45MATERX
10$12,716,711$11,119,257.82$56,776$9,798.13+$12.66MATERX

ATERX vs MRK: Complete Analysis 2026

ATERXStock

The investment seeks long-term growth of capital. The fund pursues opportunistic growth by investing in a global universe of companies whose business activities the Adviser believes position the company to benefit from certain sustainable investment themes that align with one or more of the United Nations Sustainable Development Goals SDGs. The Adviser employs a combination of "top-down" and "bottom-up" investment processes with the goal of identifying securities of companies worldwide, that fit into sustainable investment themes.

Full ATERX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ATERX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATERX vs SCHDATERX vs JEPIATERX vs OATERX vs KOATERX vs MAINATERX vs JNJATERX vs ABBVATERX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.